Effect of Liraglutide on Glucose Profiles and Gastric Emptying in Subjects With Type 2 Diabetes

Sponsor
Novo Nordisk A/S
Study ID
NCT01508923
Phase
PHASE2
Status
Completed

Conditions

Eligibility Criteria

Sex
ALL
Age
18 Years - N/A
Healthy Volunteers
Not accepted

Interventions

  • liraglutide — DRUG
    6 mcg/kg injected subcutaneously daily in each treatment period in random order. In total, subjects are treated 9-10 days
  • placebo — DRUG
    6 mcg/kg injected subcutaneously daily in each treatment period in random order. In total, subjects are treated 9-10 days

Study Details

This trial is conducted in Europe. The aim of this trial is to determine the effect of NNC 90-1170 (liraglutide) on glucose and hormonal profiles, fasting gluconeogenesis and insulin secretion in subjects with type 2 diabetes.

Key Dates

Start date
May 31, 2001
Status verified
Jan 2017
Primary completion
Feb 28, 2002
Completion
Feb 28, 2002

Study Design

Enrollment
17 participants (actual)
Allocation
RANDOMIZED
Intervention model
CROSSOVER
Primary purpose
TREATMENT

Arms

  • Experimental: Treatment period 1
  • Placebo Comparator: Treatment period 2

Primary Outcome Measure

24-hour glucose profiles after three fixed meals

Related Studies